The complexity of ADHD: diagnosis and treatment of the adult patient with comorbidities.

The complexity of ADHD: diagnosis and treatment of the adult patient with comorbidities. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

The complexity of ADHD: diagnosis and treatment of the adult patient with comorbidities. Abstract Text:

Jeffrey H Newcorn,Margaret Weiss,Mark A Stein,

Attention-deficit/hyperactivity disorder (ADHD) is an impairing but usually treatable condition. Popular culture propagates the myth that ADHD recedes with age; this is not the case. Although it is common, <20% of adults with ADHD are diagnosed or treated. Adults with ADHD show significant comorbidities with depressive disorders, anxiety disorders, substance use, oppositional defiant disorder, personality disorders, sleep problems, and learning disabilities. However, symptoms that result from ADHD, such as mood symptoms or lability, are often mistaken for comorbid disorders. Comorbidity with ADHD impacts treatment compliance, treatment response, and patient insight. Insufficient data on the interaction between ADHD and comorbidities impedes proper diagnosis and treatment. Better clinical tools for assessing these conditions are needed. Food and Drug Administration-approved pharmacologic treatments for adult ADHD include stimulants, dexmethylphenidate, and the nonstimulant atomoxetine. Effect sizes of approved medicines at approved doses are half those seen in children. Adults may also need longer duration of medication effects than children. Short-acting stimulants are likely to result in poorer adherence and have a higher risk for diversion or abuse. Risk of abuse is a major concern; stimulant treatments are controlled substances, and children with ADHD show increased risk of substance abuse. Psychosocial interventions may be beneficial in treating both ADHD and comorbidities.In this expert roundtable supplement, Margaret Weiss, MD, PhD, presents a comprehensive overview of complications surrounding differential diagnosis in adults with ADHD. Next, Mark A. Stein, PhD, reviews evaluation, comorbidity, and development of a treatment plan in this population. Finally, Jeffrey H. Newcorn, MD, provides a discussion on the pharmacologic options available for adults with ADHD, considering dosages specific to adults and common comorbidities.

The complexity of ADHD: diagnosis and treatment of the adult patient with comorbidities. Publishing Authors By Initials

JH Newcorn,M Weiss,MA Stein,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

The complexity of ADHD: diagnosis and treatment of the adult patient with comorbidities. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: CNS spectrums

VOLUME: 12

Page Numbers: 1-13

Journal Abbreviation:

ISSN: 1092-8529

DAY: 1

MONTH: Aug

YEAR: 2007

The complexity of ADHD: diagnosis and treatment of the adult patient with comorbidities. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9702877

The complexity of ADHD: diagnosis and treatment of the adult patient with comorbidities. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: The complexity of ADHD: diagnosis and treatment of the adult patient with comorbidities. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for The complexity of ADHD: diagnosis and treatment of the adult patient with comorbidities.

AFFILIATION: Division of Child and Adolescent Psychiatry, Department of Psychiatry, The Mount Sinai School of Medicine, New York, NY, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: CNS Spectr

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The complexity of ADHD: diagnosis and treatment of the adult patient with comorbidities Related Publications

• Alterations in intranuclear localization of Runx2 affect biological activity.
• Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro.
• Can differences in breast cancer utilities explain disparities in breast cancer care?
• Characterization of small amounts of peptides and proteins.
• Choosing earlier therapy for muscle-invasive bladder cancer.
• Comparability of functional MRI response in young and old during inhibition.
• Coping and burden among informal HIV caregivers.
• Correlates of condom use and reasons for condom non-use among drug users.
• Differential regulation of the two principal Runx2/Cbfa1 n-terminal isoforms in response to bone morphogenetic protein-2 during development of the osteoblast phenotype.
• Disability and poor quality of life associated with comorbid anxiety disorders and physical conditions.
• Eating disorders and substance use; An examination of behavioral associations.
• Endothelial dysfunction, erectile dysfunction, and coronary heart disease: the pathophysiologic and clinical linkage.
• Establishment of histone gene regulation and cell cycle checkpoint control in human embryonic stem cells.
• In search of mixed anxiety-depressive disorder: a primary care study.
• Is the ankle-brachial index a useful screening test for subclinical atherosclerosis in asymptomatic, middle-aged adults?
• Managing concomitant cardiac disease and erectile dysfunction.
• Natural History: Wheeze from childhood to adulthood.
• Pathologic guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature.
• Plasma homovanillic acid correlates inversely with history of learning problems in healthy volunteer and personality disordered subjects.
• Post-traumatic stress disorder in children.
• Pregnancy attitudes and contraceptive plans among women entering jail.
• Rate controlling steps in fatty acid oxidation by unloaded rodent soleus muscle.
• Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone.
• Relocation of older australians.
• Self-cognitions in antisocial alcohol dependence and recovery.
• Self-renewal of human embryonic stem cells is supported by a shortened G1 cell cycle phase.
• Slow-release and injected progesterone treatments enhance acute recovery after traumatic brain injury.
• The development of cortical multisensory integration.
• The enantiomer of progesterone acts as a molecular neuroprotectant after traumatic brain injury.
• The histone gene transcription factor HiNF-P stabilizes its cell cycle regulatory co-activator p220NPAT.